Henry Brem

Prof. Henry Brem

Neurosurgery, Johns Hopkins University, Baltimore, Maryland, USA
orcid
Harvey Cushing Professor and Chief of Neurosurgery at Johns ...

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2007 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
NMNeena Marupudi
Neena Marupudi
JHJames E Han
James E Han
KLKhan W Li
Khan W Li
VRViolette M Renard
Violette M Renard
BTBetty M Tyler
Betty M Tyler
Henry BremHenry Brem
Henry Brem
(2007). Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opinion on Drug Safety: Vol. 6, No. 5, pp. 609-621.

1 July 2001 in Journal of Controlled Release
Verified
Journal Article
Closed access
Henry BremHenry Brem
Henry Brem
PGP Gabikian
P Gabikian

26 January 2007 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SBSarah Brem
Sarah Brem
BTBetty Tyler
Betty Tyler
KLKhan Li
Khan Li
GPGustavo Pradilla
Gustavo Pradilla
FLFederico Legnani
Federico Legnani
Henry BremHenry Brem
Henry Brem

26 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
EYEilam Yeini
Eilam Yeini
POPaula Ofek
Paula Ofek
Sabina PozziSabina Pozzi
Sabina Pozzi
NANitzan Albeck
Nitzan Albeck
DBDikla Ben-Shushan
Dikla Ben-Shushan
RSRonit Satchi-Fainaro
Ronit Satchi-Fainaro
Glioblastoma (GB) is a highly invasive type of brain cancer exhibiting poor prognosis. As such, its microenvironment plays a crucial role in its progression. Among the brain stromal cells, the microglia were shown to facilitate GB invasion and immunosuppression. However, the reciprocal mechanisms by which GB cells alter microglia/macrophages behavior are not fully understood. We propose that these mechanisms involve adhesion molecules such as the Selectins family. These proteins are involved in immune modulation and cancer immunity. We show that P-selectin mediates microglia-enhanced GB proliferation and invasion by altering microglia/macrophages activation state. We demonstrate these findings by pharmacological and molecular inhibition of P-selectin which leads to reduced tumor growth and increased survival in GB mouse models. Our work sheds light on tumor-associated microglia/macrophage function and the mechanisms by which GB cells suppress the immune system and invade the brain, paving the way to exploit P-selectin as a target for GB therapy.

1 November 1990 in Biomaterials
Verified
Journal Article
Open access
Henry BremHenry Brem
Henry Brem
Brain tumours are difficult to treat by conventional methods. A biodegradable polymer, poly-[bis(p-carboxyphenoxy)propane sebacic acid] with a nitrosourea, carmustine, has been demonstrated to be biocompatible in the brains of experimental animals and to release drugs in a predictable sustained manner. Carmustine impregnated in polymers appears to be more effective than when delivered by standard methods. A Phase I clinical study has demonstrated the safety of this approach in treating brain tumours and a Phase III placebo-controlled study is currently underway. Other applications of the polymer in the treatment of brain diseases are discussed.

25 April 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
FWFeihu Wang
Feihu Wang
QHQian Huang
Qian Huang
HSHao Su
Hao Su
MSMingjiao Sun
Mingjiao Sun
ZWZeyu Wang
Zeyu Wang
HCHonggang Cui
Honggang Cui
The unique cancer-associated immunosuppression in brain, combined with a paucity of infiltrating T cells, contributes to the low response rate and poor treatment outcomes of T cell-based immunotherapy for patients diagnosed with glioblastoma multiforme (GBM). Here, we report on a self-assembling paclitaxel (PTX) filament (PF) hydrogel that stimulates macrophage-mediated immune response for local treatment of recurrent glioblastoma. Our results suggest that aqueous PF solutions containing aCD47 can be directly deposited into the tumor resection cavity, enabling seamless hydrogel filling of the cavity and long-term release of both therapeutics. The PTX PFs elicit an immune-stimulating tumor microenvironment (TME) and thus sensitizes tumor to the aCD47-mediated blockade of the antiphagocytic “don’t eat me” signal, which subsequently promotes tumor cell phagocytosis by macrophages and also triggers an antitumor T cell response. As adjuvant therapy after surgery, this aCD47/PF supramolecular hydrogel effectively suppresses primary brain tumor recurrence and prolongs overall survivals with minimal off-target side effects.